Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 1,100 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,100 shares of the stock in a transaction dated Friday, July 24th. The shares were acquired at an average price of $12.88 per share, for a total transaction of $14,168.00. Following the acquisition, the chief executive officer directly owned 5,607,702 shares of the company’s stock, valued at $72,227,201.76. This represents a 0.02% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, July 23rd, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.14 per share, for a total transaction of $32,850.00.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI traded up $0.17 during midday trading on Tuesday, reaching $13.62. 80,197 shares of the stock were exchanged, compared to its average volume of 246,025. The business has a 50-day simple moving average of $21.88 and a two-hundred day simple moving average of $24.35. The company has a market capitalization of $199.84 million, a price-to-earnings ratio of -8.67 and a beta of 1.40. Greenwich LifeSciences, Inc. has a 12 month low of $7.78 and a 12 month high of $34.10.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GLSI. HC Wainwright raised their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $57.00.

Hedge Funds Weigh In On Greenwich LifeSciences

Several institutional investors have recently modified their holdings of GLSI. Bank of America Corp DE grew its holdings in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after buying an additional 1,322 shares in the last quarter. Strs Ohio purchased a new stake in Greenwich LifeSciences during the first quarter valued at $177,000. Rhumbline Advisers boosted its holdings in Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the period. Geode Capital Management LLC increased its stake in shares of Greenwich LifeSciences by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after purchasing an additional 1,972 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $509,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.